(Total Views: 621)
Posted On: 06/05/2022 8:30:18 PM
Post# of 154137
Bad news for Gilead:
https://www.reuters.com/business/healthcare-p...022-06-05/
For mTNBC, PFS SOC 2-3 months; Trodelvy 4.8 months; LL 6.2 months; Enhertu 6.6 months (includes mTNBC, but other cancers as well and that's why it's high, because of the easier cancers to treat);
Overall Survivability: SOC 6 months; Trodelvy 12 months; LL 12.5 months
For HER-2 BC: Enhertu PFS 10.1 months; SOC 5.4 months
Enhertu OS: 23.9 months; SOC 17.5 months;
Just bear in mind, Enhertu is not used for mTNBC which has the worst prognosis and the shortest PFS and OS.
Enhertu ongoing phase III trial involves over 550 patients with so-called HER2-low breast cancer - most with tumours that were hormone-sensitive - whose disease had spread and had undergone at least one round of chemotherapy.
https://www.reuters.com/business/healthcare-p...022-06-05/
Quote:
Hormone-sensitive patients who received Enhertu also went an average of 10.1 months before their disease began to worsen - a measure known as progression free survival (PFS) - compared with 5.4 months for chemotherapy, which was statistically significant.
Enhertu more than doubled the PFS for hormone-insensitive patients at 6.6 months versus 2.9 months for chemotherapy.
Quote:
The interim analysis showed Enhertu prolonged survival by an additional 6.4 months in patients with hormone-sensitive tumours. Patients in the group lived for a median of 23.9 months versus 17.5 months for chemotherapy.
Quote:
Enhertu more than doubled the PFS for hormone-insensitive patients at 6.6 months versus 2.9 months for chemotherapy.
For mTNBC, PFS SOC 2-3 months; Trodelvy 4.8 months; LL 6.2 months; Enhertu 6.6 months (includes mTNBC, but other cancers as well and that's why it's high, because of the easier cancers to treat);
Overall Survivability: SOC 6 months; Trodelvy 12 months; LL 12.5 months
For HER-2 BC: Enhertu PFS 10.1 months; SOC 5.4 months
Enhertu OS: 23.9 months; SOC 17.5 months;
Just bear in mind, Enhertu is not used for mTNBC which has the worst prognosis and the shortest PFS and OS.
Enhertu ongoing phase III trial involves over 550 patients with so-called HER2-low breast cancer - most with tumours that were hormone-sensitive - whose disease had spread and had undergone at least one round of chemotherapy.
(3)
(0)
